Roivant Sciences to acquire Silicon Therapeutics for $450m.

Roivant Sciences, a pharmaceutical company, agreed to acquire Silicon Therapeutics, a computational drug discovery company, for $450m. “By joining forces with Roivant, we can significantly accelerate making this vision a reality. Roivant has an impressive track record in clinical execution and building and deploying technology platforms to power pharmaceutical research, development and commercialization," Lanny Sun, Silicon Therapeutics Co-Founder and CEO.